Keywords: Takeda, Nycomed, M&A
Takeda finalizes 9.6 billion-euro buy of Nycomed and names new CEO
Article | 02 October 2011
With the completion of all regulatory and competition authority investigations, Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) says it ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
